

Angivent MR

PRESENTATION

Angivent ® MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.

DESCRIPTION

Trimetazidine Hydrochloride has been proven to exert antianginal properties due to its specific metabolic mechanism of action. Trimetazidine Hydrochloride reduces the metabolic damage caused during ischemia, by acting on a critical step in cardiac metabolism: fatty acid β -oxidation. This is made possible by a selective inhibition of an enzyme of fatty acid β -oxidation: the long-chain 3-ketoacyl CoA thiolase (3-KAT). This inhibition results in reduction in fatty acid oxidation & stimulation of glucose oxidation.

Thus, the coupling of glycolysis with glucose oxidation is improved and ATP production is further increased, while the deleterious consequences of acidosis and of Ca^{2+} overload are limited.

INDICATION

Long-term treatment of angina pectoris.

DOSAGE & ADMINISTRATION

One tablet at mealtimes in the morning and evening.

CONTRAINDICATIONS

Hypersensitivity to Trimetazidine Hydrochloride.

SIDE EFFECTS

Rare cases of gastrointestinal disorders.

USE IN PREGNANCY AND LACTATION

Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.

Breastfeeding: In the absence of data, breastfeeding is not recommended during treatment.

STORAGE CONDITION

Store in a cool and dry place, protected from light and moisture. Keep out of the reach of the children.

HOW SUPPLIED

Angivent ® MR Tablet: Each box contains 3 x 10 tablets in blister pack.